We investigated 11 beta hydroxysteriod dehydrogenase type 1 (11bHSD-1) sequence variants in 103 healthy overweight (BMI 42 s.d.) and 160 nonoverweight (BMI -2 to +2 SD) children to examine the associations between body composition and 11bHSD-1 polymorphisms. A total of 4.3% of children were homozygous and 30.0% heterozygous for an adenine insertion in intron 3 (ins4436A). By ANCOVA (adjusting for age, sex, race, and height), BMI-s.d. differed according to ins4436A genotype (Po0.005), with the greatest BMI-SD for ins4436A homozygotes (mean 7s.d., 3.473.4, vs heterozygotes, 0.875.5, or wildtype, 1.877.5). Homozygotes also had greater waist circumference, waist-to-hip ratio, and insulin resistance indices than heterozygote or wild-type children (all Po0.05), but no significant differences in trunk fat by DXA, or in serum lipids. We conclude an intronic 11bHSD-1 gene polymorphism is associated with greater body mass, altered body composition, and insulin resistance in children. 11bHSD-1 may be one of the genes relevant for pediatric-onset obesity and its complications.
Introduction
Increased concentrations of glucocorticoid due to increased conversion of the inactive glucocorticoid cortisone to its active metabolite, cortisol by 11 beta hydroxysteroid dehydrogenase type I (11bHSD-1), 1 may be involved in obesity and its complications. [2] [3] [4] [5] Although circulating cortisol concentrations are invariably normal in patients with obesity, 6 the autocrine or local paracrine effects of conversion of cortisone to cortisol in adipose tissue, and especially in omental fat, may play a role in central obesity. Alterations in 11bHSD-1 activity have functional significance for body composition in rodents. 7 Mice overexpressing 11bHSD-1 in adipocytes demonstrate increased adipose tissue corticosterone (the active metabolite in mice), hyperphagia, greater weight gain (particularly when given a high fat diet), increased accumulation of visceral adipose tissue, insulin resistance, and increased expression of lipoprotein lipase in omental fat. 7 We have recently observed an abnormally high ratio of urinary cortisol/cortisone metabolites in patients with hypothalamic obesity, 8 suggesting an enhanced activity of 11bHSD-1. Other studies show that a higher BMI is associated with increased inactivation of cortisol in the liver of obese men and women, 9,10 as demonstrated by higher excretion of cortisol metabolites, accompanied by decreased activity of 11bHSD-1 in liver, but a marked enhancement of 11bHSD-1 activity in subcutaneous fat. Controversy exists regarding whether there is a compatible increase in 11bHSD-1 mRNA in subcutaneous and omental fat. 11, 12 To date, no polymorphisms significantly associated with obesity or its complications have been found in the 11bHSD-1 gene. 13 A recent study, conducted to search for genetic associations between two (CA)n dinucleotide microsatellite repeats within intron 4 of the 11bHSD-1 gene and obesityrelated phenotypes, found weak associations between genotypes and waist: hip ratio, suggesting that allelic 11bHSD-1 variability might influence susceptibility for central obesity. 14 We therefore analyzed the 11bHSD-1 gene sequence in a cohort of overweight and normal weight children, seeking genetic variants associated with obesity, central obesity, or the metabolic elements that comprise syndrome X.
Materials and methods

Subjects
A total of 263 children aged 5-18 y, who were recruited for metabolic studies at the NIH from the community, were enrolled. The group included 154 female subjects, and 109 male subjects. There were 136 white subjects, of white parents and grandparents, 106 African Americans of AfricanAmerican parents and grandparents, six Asians, five Hispanic, and 10 of mixed racial background. Age (mean 10.273.0 y) ranged from 5.5 to 18.7 y. By design, the study population was enriched for obesity. In all, 103 children were overweight, with BMI 42 s.d. for age and sex. Of them, 160 children were normal weight. All subjects were healthy, with normal electrolyte, hepatic, and thyroid function. None had any significant physical illness, and none were taking medications known to affect body weight. The NICHD institutional review board approved the protocol. Informed consent was obtained from parents and assent from children.
Anthropometric measurements BMI-s.d. score was determined using the tables of Frisancho. 15 Body adiposity was determined by dual-energy X-ray absorptiometry (DXA) using the Hologic QDR 2000 (Waltham, MA, USA), as described previously. 16 Body circumferences and skinfold thickness measurements were obtained as recommended.
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The homeostasis model assessment for insulin resistance index (HOMA-IR) was estimated using the formula: 18 HOMA-IR ¼ {fasting insulin (mIU/l) Â fasting glucose (mmol/l)}/22.5.
Analysis of sequence variants
Genomic DNA was isolated from blood samples. Eight pairs of primers were designed to amplify eight segments of the target gene, including all exons, exon-intron borders, and the proximal promoter region. PCR amplification was accomplished using a GeneAmp PCR reagent kit and system 9700. Direct sequencing was performed for 44 subjects (38 obese, six lean), using an ABI 377 automated sequencer. Sequencing data were analyzed using Sequencer for windows 4.05 (Sequencher, Gene Codes Ann Arbor, MI, USA).
One suspected site of polymorphism found through sequencing was verified using restriction endonuclease XcmI, (New England BioLabs Inc., Beverly, MA, USA). This insertion created a new digestion site for XcmI, cutting the PCRgenerated 262 bp segment containing exon 3 and the proximal portion of intron 3 into fragments of 195 and 67 bp.
Data analysis
Logarithmic transformation was performed before analysis for clinical laboratory, anthropometric, and DXA measurements; back-transformed geometric means are reported. The comparisons of the phenotypes among genotypes were evaluated by using analysis of covariance (ANCOVA), so that age, height, race, and gender could be accounted for as required for analyses. The primary analysis compared individuals homozygous for the identified polymorphism against those having either one or two wild-type alleles.
Results
Only one polymorphism identified through sequencing was verified using restriction endonuclease analysis: insertion of an adenine at position 4436 13 within intron 3 (ins4436A). In ANCOVA analyses that included age, sex, race, and height as covariates ( 
Discussion
Epidemiological studies indicate there is a significant familial component to obesity. [19] [20] [21] [22] Monogenic forms of obesity, due to mutations notably in the genes encoding leptin and its signal transduction pathway, have been described, but explain a small share of the obese. The role of most genetic factors in obesity is likely to be polygenic, manifested through an interaction between several susceptibility genes that individually have relatively small effects. We report here a common polymorphic site within the 11bHSD-1 gene, located in intron 3 in a cohort of 263 obese and nonobese subjects that is associated with greater BMI, greater waist-to-hip ratio, and insulin resistance. 11bHSD-1 is expressed highly in omental depots and may be relevant for 11bHSD-1 and pediatric obesity L Gelernter-Yaniv et al how glucocorticoids promote visceral obesity. As insulin resistance and high waist-to-hip ratio are associated with high visceral abdominal adipose tissue (VAT), this study's findings would be consistent with an increase in VAT in ins4436A homozygotes. Based on the effects of 11bHSD-1 gene overexpression in mouse adipocytes, 7 and on the enhanced activity of 11bHSD-1 in adipocytes of obese men and women, ins4436A homozygotes might be predicted to be associated with increased activity of the 11bHSD-1 enzyme. A dose-dependent relation has not been shown, as heterozygotes do not show a trend towards a similar phenotype, and this polymorphism does not appear likely to affect gene expression directly. In a previous study, the ins4436A polymorphism was found in four of eight obese patients and in one lean control, 13 but no further studies were done. The functional consequences of this polymorphism should be assessed by examining the urinary glucocorticoid metabolite ratio in vivo or by in vitro studies. Studies of other populations should also be performed, since the number of homozygotes was small. Supporting a role for 11bHSD-1 allelic variation for body composition is a recent study that examined genetic association between (CA)n dinucleotide microsatellite repeats within intron 4 of the 11bHSD-1 gene. Although, no relation were found between individual allelic genotypes and BMI, borderline significant associations were found between clinical phenotypes (a raised (5bTHF+5aTHF)/THE ratio or waist:hip ratio) and genotypes (over-representation of long alleles for a CA15 microsatellite marker or of short alleles for an adjacent CA19 marker in intron 4 of the 11bHSD-1 gene). 14 We conclude that a polymorphism in the 11bHSD-1 gene is associated with susceptibility to pediatric-onset obesity and its complications. Whether this association has been detected by chance, is due to an association with the identified 11bHSD-1 gene variant, due to a different polymorphism in 11bHSD-1, or due to linkage disequilibrium with another nearby gene on chromosome 1q32.2-41 remains to be determined. 11bHSD-1 and pediatric obesity L Gelernter-Yaniv et al
